“As we look at our opportunity to satisfy the global demand and protect as many lives as we can going forward, we will be supported by the increased supply and capacity that we have coming online commencing 2023. And we expect that, that additional supply will come online over the course of ‘23, ‘24 and ‘25.”

In context

“fy where the supply is coming from geographically? Thank you. Caroline Litchfield: This is Caroline. I’ll take a shot at answering your question. So GARDASIL continues to be a very strong growth driver for our company and will be long into the future given to date only 9% of the world’s eligible population are vaccinated. In terms of the quarter results, we saw growth in the U. S., which was largely driven by the CDC timing. In the third quarter of 2021, there was an approximate $125 million buy-in by the CDC. In the third quarter of ‘22, there was an approximate buy-in of $250 million. So year-over-year, that contributed to growth to the tune of approximately $120 million plus. We do expect the majority of that buy-in by the CDC in the third quarter to come out during the fourth quarter. As we look at our opportunity to satisfy the global demand and protect as many lives as we can going forward, we will be supported by the increased supply and capacity that we have coming online commencing 2023. And we expect that, that additional supply will come online over the course of ‘23, ‘24 and ‘25. And therefore, we remain very confident in our ability to protect more lives, to drive growth long into the future, including doubling the revenue of GARDASIL in the year 2030 compared to where we were in 2021. Peter Dannenbaum: Great. Thank you, Colin. Next question please Leo. Operator: Next is Seamus Fernandez with Guggenheim. Please go ahead. Seamus Fernandez: Thanks so much for the question. So, I really wanted to ask a question on sotatercept and perhaps the endpoints that surprised you the most. The feedback that we are getting from thought leaders is that the benefit on clinical worsening actually coming as early as it did was a genuine surprise and suggests upside. Just wondering, Dean, where you fit in that point of discussion and perhaps what you are looking forward to in some”